Who
Stephen W. Webster
Director
Company insider
Files Form 4 as: Director, NextCure; Director, Cullinan Therapeutics; Director, Eloxx Pharmaceuticals; Director, Gritstone bio; Director, Tcr2 Therapeutics; Director, Nabriva Therapeutics; Director, Viking Therapeutics; Chief Financial Officer, Spark Therapeutics.
In numbers
- Trades disclosed
- 125
- Buys
- 4
- Sells
- 10
- Bought
- $155K
- Sold
- $4.7M
- Companies
- 12
- Companies where not an officer
- 9
- First trade
- 27 Oct 2008
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,319 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,319 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,587 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,587 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,513 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —103,600 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —7,379 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone bio | SEC FORM 4 Code J | —25,000 at $0.00 | filing |
| 26 Jun 2024filed 27 Jun 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,806 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Gritstone biooption or derivative | SEC FORM 4 Code A | —7,379 at $0.00 | filing |
| 26 Apr 2024filed 30 Apr 2024 | Gritstone biooption or derivative | SEC FORM 4 Code A | —103,600 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,250 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,450 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,800 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,100 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,100 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Stephen W. Webster; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.